Join CervoMed (#CRVO) for a virtual KOL event on Tues. July 23 at 10am ET to discuss neflamapimod for dementia with Lewy Bodies, featuring John-Paul Taylor, MBBS (hons), MRCPsych, PhD (Newcastle University) and Ralph A. Nixon, MD, PhD (New York University Grossman School of Medicine). Register here: https://bit.ly/3zFoEAA
LifeSci Advisors, LLC’s Post
More Relevant Posts
-
In case you missed it, here's Part 2 of our interview with Mercy neurologist Dr. Howie Zheng and Jocelyn Henning, PA, Director, Mercy Stroke Program, on the latest edition of #MEDOSCOPY:
To view or add a comment, sign in
-
During the last fifteen years, UPMC has treated more than 1,200 cases of thoracic #aortic dissections (TAD) and is one of the leading research centers in the U.S. studying the pathophysiology of the disorder while also publishing on its institutional outcomes, notably on the role malperfusion syndrome plays in TAD and how to optimally manage patient care. Ibrahim Sultan, MD, FACS, FACC, further discusses some of the insights, treatment approaches, and research learnings from UPMC in caring for patients with TAD in this new article: https://lnkd.in/eyVhMzDF
To view or add a comment, sign in
-
“As a neurologist, a clinical researcher and someone who has seen Alzheimer’s in my own family, I’m grateful we are seeing such progress in our field. But, Abby, we need help from your readers to test these promising medications before the devastating symptoms of Alzheimer’s disease are apparent.” In a letter to Dear Abby, Reisa Sperling, M.D., a professor at Harvard Medical School, stresses the importance of clinical trial participation. Abby encourages readers to enroll in TrialMatch, our free clinical trial matching service. Read the letter at https://bit.ly/3v2oukr and learn more about TrialMatch at alz.org/TrialMatch.
To view or add a comment, sign in
-
Attending AD/PD in Lisbon this week? CuraSen's chief medical officer, Gabriel Vargas, MD, PhD, will give an oral presentation of impressive Phase 2a data in Alzheimer’s and Parkinson’s disease patients this Sat March 9 at 17:25 UTC. CuraSen’s combination adrenergic activator, CST-2032/CST-107, achieved statistically and clinically important effects across several cognitive domains, such as memory, attention, executive function, facial recognition and impulse control — areas known to be impacted by adrenergic function. The company plans to initiate longer studies with CST-2032/CST-107 in AD/PD patients with MCI later this year. https://lnkd.in/ghSxqppm #Alzheimer's#Parkinson's#MCI
To view or add a comment, sign in
-
ECTRIMS Patient Community Day is a day for people living with multiple sclerosis and related diseases to learn from top neurological experts about progress and updates being made in the treatment of their conditions. In this programme, a round-table panel of MS experts will discuss the latest progress being made in research, treatment and care – with a focus on trending topics – with plenty of opportunities for participants to ask questions about the latest research affecting their condition. “Every year, we bring thousands of researchers from around the world together to advance our knowledge of MS and related neurological disorders. But the most important members of our community are the patients themselves." ECTRIMS President, @Mar Tintore Subirana 🧠❤️ Sharing the latest research in MS, MOGAD, NMOSD & other neurological conditions with the people most impacted by them. 20 September 2024 | Copenhagen, Denmark & online Register now: https://buff.ly/3YAGyP8 #ECTRIMS2024 #MS #NMOSD #MOGAD
To view or add a comment, sign in
-
What an informative discussion on #HoLEP. Glad Richard Wolf Medical Instruments Corporation can help spread the word on this effective procedure for #BPH. #urology #urosome
Listen to our HoLEP Queen, Dr. Amy Krambeck discuss procedural techniques and outcomes of Holmium Laser Enucleation of the Prostate (#HoLEP) for the treatment of lower urinary tract symptoms (#LUTS) secondary to #BPH. Northwestern Medicine Northwestern University - The Feinberg School of Medicine MCGAW MEDICAL CENTER OF NORTHWESTERN UNIVERSITY Watch Here: https://lnkd.in/g8MXZYYF
To view or add a comment, sign in
-
“As a neurologist, a clinical researcher and someone who has seen Alzheimer’s in my own family, I’m grateful we are seeing such progress in our field. But, Abby, we need help from your readers to test these promising medications before the devastating symptoms of Alzheimer’s disease are apparent.” In a letter to Dear Abby, Reisa Sperling, M.D., a professor at Harvard Medical School, stresses the importance of clinical trial participation. Abby encourages readers to enroll in TrialMatch, our free clinical trial matching service. Read the letter at https://bit.ly/3v2oukr and learn more about TrialMatch at alz.org/TrialMatch.
To view or add a comment, sign in
-
“As a neurologist, a clinical researcher and someone who has seen Alzheimer’s in my own family, I’m grateful we are seeing such progress in our field. But, Abby, we need help from your readers to test these promising medications before the devastating symptoms of Alzheimer’s disease are apparent.” In a letter to Dear Abby, Reisa Sperling, M.D., a professor at Harvard Medical School, stresses the importance of clinical trial participation. Abby encourages readers to enroll in TrialMatch, our free clinical trial matching service. Read the letter at https://bit.ly/3v2oukr and learn more about TrialMatch at alz.org/TrialMatch.
To view or add a comment, sign in
-
In this study Yakeel Quiroz, et al. analyzed data from 27 participants with one copy of the APOE3Ch variant among 1077 carriers of the PSEN1E280A variant in a kindred from Antioquia, Colombia, to estimate the age at the onset of cognitive impairment and #Dementia in this group as compared with persons without the APOE3Ch variant. Data showed that having only one copy of the APOE3 Christchurch variant was enough to confer some protection against PSEN1 autosomal dominant #AlzheimersDisease. Learn More in the New England Journal of Medicine https://lnkd.in/e9mfgceJ APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer’s Disease - Yakeel T. Quiroz, PhD, David Aguillon, Daniel Aguirre-Acevedo, Daniel Vasquez, Yesica Zuluaga, Ana Y. Baena, Lucia Madrigal, Joseph Arboleda-Velasquez, et al. Massachusetts General Hospital Harvard Medical School, Brigham and Women's Hospital Schepens Eye Research Institute, Mass. Eye and Ear GNA - Grupo de Neurociencias de Antioquia, Facultad de Medicina Universidad de Antioquia Institute of Neuropathology, University Medical Center Hamburg–Eppendorf UC Santa Barbara Banner Alzheimer’s Institute University of Arizona College of Medicine – Tucson Arizona State University - Tempe https://lnkd.in/ez-ENVbb
To view or add a comment, sign in
-
Junior Resident(Non-Academic) in Department of Transfusion Medicine at Dr. RMLIMS, Lucknow, UP, India | Healthcare Leadership | International Delegation | USMLE Aspirant
Exciting news! My latest research article has been published! This study explores Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Comprehensive Review. I'm thrilled to share my research with the community and look forward to your thoughts and feedback. Access the full article here: #research #publication #innovation
Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Comprehensive Review
cureus.com
To view or add a comment, sign in
15,335 followers